Newsroom

LONDON--(BUSINESS WIRE)--  Re: ATLAS FUNDING 2023 -1 PLC GBP 10,132,000.00 MATURING: 20-Jan-2061 ISIN: XS2601488773 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 20-Jan-2026 TO 20-Feb-2026 HAS BEEN FIXED AT 6.48 PCT DAY BASIS: ACTUAL/365(FIX) INTEREST PAYABLE VALUE 20-Feb-2026 WILL AMOUNT TO: GBP 58,713.67 PER GBP 10,666,000.00 DENOMINATION  ...

INCHEON, Zuid-Korea--(BUSINESS WIRE)--Celltrion, Inc. heeft vandaag nieuwe gegevens uit een post-hocanalyse van de cruciale LIBERTY-onderzoeken (LIBERTY-CD en LIBERTY-UC) bekendgemaakt. Hierin wordt aangetoond dat subcutaan (SC) infliximab bij de meeste patiënten met de ziekte van Crohn (CD) en colitis ulcerosa (UC) de respons herstelde en handhaafde, met aanhoudende werkzaamheid, veiligheid en persistentie tot week 102.1 De gegevens worden gepresenteerd in de vorm van een posterpresentatie tij...

LONDON--(BUSINESS WIRE)--  Re: Atlas Funding 2024-1 PLC GBP 7,695,000.00 MATURING: 20-Sep-2061 ISIN: XS2819820288 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 20-Jan-2026 TO 20-Feb-2026 HAS BEEN FIXED AT 5.93 PCT DAY BASIS: ACTUAL/365(FIX) INTEREST PAYABLE VALUE 20-Feb-2026 WILL AMOUNT TO: GBP 40,763.57 PER GBP 8,091,818.35 DENOMINATION  ...

LONDON--(BUSINESS WIRE)--  Re: ATLAS FUNDING 2025-1 PLC GBP 4,752,000.00 MATURING: 20-Jul-2062 ISIN: XS3037719138 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 20-Jan-2026 TO 20-Feb-2026 HAS BEEN FIXED AT 7.73 PCT DAY BASIS: ACTUAL/365(FIX) INTEREST PAYABLE VALUE 20-Feb-2026 WILL AMOUNT TO: GBP 31,203.51 PER GBP 4,752,000.00 DENOMINATION  ...

INCHEON, Corea del Sud--(BUSINESS WIRE)--Celltrion, Inc. oggi ha annunciato nuovi dati derivanti da un'analisi post-hoc degli studi registrativi LIBERTY (LIBERTY-CD e LIBERTY-UC), che dimostrano che l’infliximab sottocutaneo (SC) ha ripristinato e mantenuto la risposta nella maggior parte dei pazienti con malattia di Crohn (MC) e colite ulcerosa (CU) con efficacia, sicurezza e persistenza sostenute fino alla Settimana 102.1 I dati saranno presentati in formato poster al 21o Congresso dell'ECCO...

LONDON--(BUSINESS WIRE)--  Re: Atlas Funding 2024-1 PLC GBP 15,390,000.00 MATURING: 20-Sep-2061 ISIN: XS2819820106 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 20-Jan-2026 TO 20-Feb-2026 HAS BEEN FIXED AT 5.28 PCT DAY BASIS: ACTUAL/365(FIX) INTEREST PAYABLE VALUE 20-Feb-2026 WILL AMOUNT TO: GBP 72,592.88 PER GBP 16,183,636.70 DENOMINATION  ...

LONDON--(BUSINESS WIRE)--  Re: Atlas Funding 2025-2 plc GBP 18,810,000.00 MATURING: 20-Jul-2067 ISIN: XS3212016284 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 11-Nov-2025 TO 20-Feb-2026 HAS BEEN FIXED AT 4.96 PCT DAY BASIS: ACTUAL/365(FIX) INTEREST PAYABLE VALUE 20-Feb-2026 WILL AMOUNT TO: GBP 271,885.14 PER GBP 19,800,000.00 DENOMINATION  ...

LONDON--(BUSINESS WIRE)--  Re: ATLAS FUNDING 2023 -1 PLC GBP 2,174,000.00 MATURING: 20-Jan-2061 ISIN: XS2601814754 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 20-Jan-2026 TO 20-Feb-2026 HAS BEEN FIXED AT 13.46 PCT DAY BASIS: ACTUAL/365(FIX) INTEREST PAYABLE VALUE 20-Feb-2026 WILL AMOUNT TO: GBP 26,170.06 PER GBP 2,289,000.00 DENOMINATION  ...

INCHEON, Südkorea--(BUSINESS WIRE)--Celltrion, Inc. gab heute neue Daten aus einer Post-hoc-Analyse der zulassungsrelevanten LIBERTY-Studien (LIBERTY-CD und LIBERTY-UC) bekannt, die zeigen, dass subkutanes Infliximab bei den meisten Patienten mit Morbus Crohn (MC) und Colitis ulcerosa (Cu) Krankheitskontrolle wiederherstellte und aufrechterhielt, mit anhaltender Wirksamkeit, Sicherheit und Persistenz bis zur Woche 102.1 Die Daten werden als Posterpräsentation auf dem 21. Kongress der European C...

LONDON--(BUSINESS WIRE)--  Re: Atlas Funding 2024-1 PLC GBP 4,040,000.00 MATURING: 20-Sep-2061 ISIN: XS2819820528 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 20-Jan-2026 TO 20-Feb-2026 HAS BEEN FIXED AT 7.37 PCT DAY BASIS: ACTUAL/365(FIX) INTEREST PAYABLE VALUE 20-Feb-2026 WILL AMOUNT TO: GBP 6,112.92 PER GBP 976,404.88 DENOMINATION  ...